Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

Jordan D. Berlin, MD, discusses the unmet needs in pancreatic cancer treatment and ongoing research efforts with nanoliposomal irinotecan.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Douglas B. Johnson, MD, MSCI, discusses his research examining the impact of body composition on outcomes from anti–PD-1 with or without anti–CTLA-4 therapies in melanoma and other biomarkers under exploration.

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

Vanderbilt-Ingram Cancer Center received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute and places it once again in a top group of NCI Comprehensive Cancer Centers.

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non​–small cell lung cancer.

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Jordan D. Berlin, MD, discusses the importance of more data and more effective treatment regimens in metastatic pancreatic cancer, despite the number of treatment options currently available.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies, which featured insights from Vanderbilt-Ingram Cancer Center faculty.

Jeremy L. Warner, MD, MS, discusses the goals of the COVID-19 and Cancer Consortium Registry, what other data need to be extrapolated with COVID-19, and how the virus could impact patients with cancer.

Madan Jagasia, MBBS, MS, MMHC, discusses the current treatment landscape and next steps in graft-versus-host-disease.

Cathy Eng, MD, FACP, FASCO, discusses the need to increase awareness regarding treating adolescents and young adults with colorectal cancer.

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Sam S. Chang, MD, MBA, discusses adjuvant versus salvage radiation in patients with nonmetastatic high-risk prostate cancer.

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the goals of the COLOMATE protocol in metastatic colorectal cancer (mCRC).

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses the importance of maintaining quality of life for patients treated with androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.